Narayana Hrudayalaya Ltd. has submitted to the Exchange regarding approval of the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.
NH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Smallcap 250 and 5.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Narayana Hrudayalaya reported its Q1 FY26 (quarter ended June 30, 2025) unaudited results, reviewed by Deloitte Haskins & Sells with a clean (unqualified) review report. Standalone revenue from operations rose about 8% year-on-year to Rs. 9,431 million, EBITDA grew nearly 15% to Rs. 1,955 million, while profit after tax was almost flat at Rs. 874 million (vs Rs. 864 million). On a consolidated basis, revenue grew about 15% to Rs. 15,073 million and EBITDA rose around 11% to Rs. 3,607 million, but profit after tax from continuing operations dipped about 2% to Rs. 1,961 million. The board also approved seeking shareholder approval via special resolution to issue debt securities (including NCDs) up to a revised limit of Rs. 2,500 crore in a financial year on a private placement basis. Additionally, the merger scheme of subsidiary Meridian Medical Research & Hospital Ltd. with the company has received no-objection letters from BSE and NSE and is set to be filed with NCLT.
Operational performance was steady with mid-to-high single digit revenue growth and EBITDA expansion on a standalone basis, but consolidated bottom line was marginally weaker, which may keep the stock reaction muted. The Rs. 2,500 crore debt-raising plan signals ongoing expansion plans but could mean dilution of equity or higher interest costs ahead depending on how it is deployed.